Trials / Active Not Recruiting
Active Not RecruitingNCT06678074
Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI
Phase 1b Pilot Study of Atibuclimab (IC14) for Treatment of ST-Elevation Myocardial Infarction
- Status
- Active Not Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Implicit Bioscience · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Adults who have had an ST-elevation myocardial infarction and were treated with stent placement will receive an intravenous infusion of a monoclonal antibody in order to prevent further heart muscle damage. The goal is to learn if this treatment improves some measures of heart function and inflammation. The study treatment patients will be compared to patients who receive placebo (inactive treatment).
Detailed description
Randomized, double-blind, placebo-controlled pilot study to evaluate the safety, exploratory efficacy, and pharmacokinetics of IC14 (atibuclimab) administered via a single IV infusion to patients with STEMI treated with percutaneous intervention. In additional to optional CCR2+ myocardial imaging, biomarkers, cardiac function and patient-reported outcome measures will be reported.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Atibuclimab (IC14), 20 mg/kg intravenously, once | monoclonal antibody against CD14 |
| OTHER | Placebo, 150 mL intravenously, once | sterile normal saline for injection |
Timeline
- Start date
- 2025-02-06
- Primary completion
- 2026-06-01
- Completion
- 2026-09-01
- First posted
- 2024-11-07
- Last updated
- 2026-03-27
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06678074. Inclusion in this directory is not an endorsement.